Table 1.
Basic characteristics of the studies.
| Author | Year | Country | Type of study | Type of TCAE | Treatment | No. of patients | Median age | Sex (M/F) | Score (NOS) |
|---|---|---|---|---|---|---|---|---|---|
| Ueno 10 | 2009 | Japan | RCS | cTACE | RFA | 10 | 68 | 10/0 | 6 |
| TACE | 13 | 72 | 8/5 | ||||||
| Qkuwaki 11 | 2009 | Japan | RCS | cTACE | RFA | 30 | 69 | 16/14 | 6 |
| TACE | 19 | 65 | 12/7 | ||||||
| Koh 12 | 2016 | China | RCS | cTACE | RFA | 42 | 63 | 32/10 | 8 |
| TACE | 60 | 57 | 51/9 | ||||||
| Chen 13 | 2016 | China | RCS | cTACE | RFA | 32 | NA | 28/4 | 9 |
| TACE | 78 | NA | 71/7 | ||||||
| Kim 14 | 2017 | Korea | RCS | cTACE | RFA | 6 | 50 | 5/1 | 6 |
| TACE | 21 | 57.1 | 20/1 | ||||||
| Joliat 15 | 2017 | Switzerland | RCS | NA | RFA | 18 | 64 | 13/5 | 7 |
| TACE | 16 | 67 | 14/2 | ||||||
| Wang 16 | 2020 | China | RCS | cTACE DEB-TACE |
RFA | 47 | 60.6 | 34/13 | 8 |
| TACE | 32 | 61 | 28/4 | ||||||
| Kim 17 | 2020 | Korea | RCS | NA | RFA | 171 | 56 | 137/34 | 7 |
| TACE | 230 | 56 | 187/43 | ||||||
| Wang 18 | 2015 | China | PCS | NA | RFA | 162 | 52.7 | 148/14 | 8 |
| TACE | 339 | 51 | 301/38 |
RCS, retrospective cohort study; PCS, prospective cohort study; NA, not applicable; NOS, Newcastle-Ottawa scale; RFA, radiofrequency ablation; TACE, transarterial chemoembolization, cTACE, conventional TACE; DEB-TACE, drug-eluting bead TACE.